Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Developme...
Main Authors: | Jane M. Knisely, Lucas E. Buyon, Rebecca Mandt, Rebecca Farkas, Shobana Balasingam, Karin Bok, Ursula J. Buchholz, M. Patricia D’Souza, Jennifer L. Gordon, Deborah F. L. King, Tung T. Le, Wolfgang W. Leitner, Robert A. Seder, Alkis Togias, Stig Tollefsen, David W. Vaughn, Daniel N. Wolfe, Kimberly L. Taylor, Anthony S. Fauci |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-04-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-023-00654-6 |
Similar Items
-
Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies
by: Shobana Balasingam, et al.
Published: (2016-08-01) -
HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV
by: Cicala Claudia, et al.
Published: (2010-01-01) -
The potential for a controlled human infection platform in Singapore
by: Balasingam, Shobana, et al.
Published: (2014) -
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization
by: John T. Prior, et al.
Published: (2023-05-01) -
Virtual Modeling of User Populations and Formative Design Parameters
by: Benjamin M. Knisely, et al.
Published: (2020-10-01)